Biora Therapeutics, Inc.
BIOR · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -87.08 | 0.17 | 0.06 |
| FCF Yield | 174.24% | -0.00% | -5.81% | -4.12% |
| EV / EBITDA | -3.38 | 31,178.65 | -196.46 | -26.66 |
| Quality | ||||
| ROIC | 19.96% | 63.97% | 62.24% | 45.92% |
| Gross Margin | 100.00% | 65.41% | 100.00% | -13.42% |
| Cash Conversion Ratio | 0.35 | -1.69 | 2.98 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | 34.44% | 27.89% | 6.06% | -67.54% |
| Free Cash Flow Growth | 387.02% | 11.02% | 9.41% | -25.16% |
| Safety | ||||
| Net Debt / EBITDA | -2.25 | 5.77 | -28.10 | -2.34 |
| Interest Coverage | -8.05 | -22.20 | -5.63 | -7.25 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 2,441.25 | -5,913.54 | -4,094.36 | -2,101.26 |